JAK inhibitors, which target Janus kinases, have shown promising results in the treatment of various dermatologic conditions, including atopic dermatitis, psoriasis, vitiligo, connective tissue disorders, autoimmune bullous diseases and alopecia areata. In the future, it is likely that JAK inhibitors will continue to play an important role in the management of these conditions. Clinical trials are ongoing to assess the safety and efficacy of JAK inhibitors in the treatment of other dermatologic disorders, such as vitiligo and hidradenitis suppurativa.